Agacayak Elif, Keles Aysenur, Deger Ugur, Sirin Ozcelik Mehmet, Peker Nurullah, Gunduz Reyhan, Akkus Murat, Buyukbayram Huseyin
Department of Obstetrics and Gynecology, Dicle University School of Medicine, Diyarbakır, Turkey.
Department of Pathology, Dicle University School of Medicine, Diyarbakır, Turkey.
Cancer Manag Res. 2022 Mar 24;14:1247-1257. doi: 10.2147/CMAR.S353225. eCollection 2022.
This study aims to determine an important parameter in progression from pre-invasive lesions of endometrium to endometrial cancer and also evaluate the effect of this parameter on the progression of endometrial cancer.
In our study,30 patients with normal endometrial tissue (group 1), 56 patients who had endometrial hyperplasia without atypia (group 2), 36 patients who had endometrial hyperplasia with atypia (group 3), and 63 patients with endometrial cancer (group 4) were included. Age, parity, body-mass index, systemic diseases, and tumor markers of patients were evaluated. Expression levels of Ezrin, Radixin, and Moesin proteins were immunohistochemically evaluated in terms of frequency, intensity, and score value.
When we compared hyperplasia cases with or without atypia; frequency, and score value of ezrin expression and frequency, intensity, and score value of moesin expression was significantly higher in patients who had hyperplasia with atypia (p:0.000 p:0.001 p:0.003, p:0.032 p: 0.035 p:0.015 p:0.005, respectively). It was observed that the frequency and score value of moesin expression were significantly higher in patients with endometrial cancer when compared with patients who had hyperplasia with atypia (p:0.003 p:0.045). The frequency of moesin expression was significantly higher in patients who had postoperative mortality (p:0.030 p:0.039).
Increased frequency of moesin expression in the preoperative period in patients with atypical hyperplasia should alert the surgeon in terms of malignancy. If the frequency of moesin expression increases in cases with endometrial cancer, the patient should be followed closely in terms of progression in the postoperative period.
本研究旨在确定子宫内膜癌前病变进展为子宫内膜癌过程中的一个重要参数，并评估该参数对子宫内膜癌进展的影响。
本研究纳入了30例子宫内膜组织正常的患者（第1组）、56例无不典型增生的子宫内膜增生患者（第2组）、36例有不典型增生的子宫内膜增生患者（第3组）以及63例子宫内膜癌患者（第4组）。对患者的年龄、产次、体重指数、全身性疾病和肿瘤标志物进行了评估。采用免疫组织化学方法，从频率、强度和评分值方面评估埃兹蛋白、根蛋白和膜突蛋白的表达水平。
当我们比较有或无不典型增生的增生病例时；有不典型增生的患者中埃兹蛋白表达的频率和评分值以及膜突蛋白表达的频率、强度和评分值显著更高（p值分别为0.000、0.001、0.003、0.032、0.035、0.015、0.005）。观察到与有不典型增生的患者相比，子宫内膜癌患者中膜突蛋白表达的频率和评分值显著更高（p值分别为0.003、0.045）。术后死亡的患者中膜突蛋白表达的频率显著更高（p值分别为0.030、0.039）。
不典型增生患者术前膜突蛋白表达频率增加应使外科医生警惕恶性肿瘤。如果子宫内膜癌病例中膜突蛋白表达频率增加，应在术后密切随访患者的病情进展。
